切换至 "中华医学电子期刊资源库"
高级检索
中华乳腺病杂志(电子版)

中华乳腺病杂志(电子版) ›› 2009, Vol. 03 ›› Issue (05) : 542 -548. doi: 10.3877/cma.j.issn.1674-0807.2009.05.012

实验研究

BP1和C-erB-2在乳腺癌中的表达
李孟圈1, 李靖若1,†(), 李江涛1   
  1. 1.450052 郑州,郑州大学第一附属医院乳腺外科
  • 收稿日期:2009-03-11 出版日期:2009-10-01
  • 通信作者: 李靖若
  • 基金资助:
    河南省医学高科技发展扶持项目(20060038)

Expressions of BP1 and C-erB-2 gene in breast cancer

Meng-quan LI1, Jing-ruo LI†,1(), Jiang-tao Ling1   

  1. 1.Breast Surgery Department,First Affiliated Hospital,Zhengzhou University,Zhengzhou 450052,China
  • Received:2009-03-11 Published:2009-10-01
  • Corresponding author: Jing-ruo LI
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

李孟圈, 李靖若, 李江涛. BP1和C-erB-2在乳腺癌中的表达[J/OL]. 中华乳腺病杂志(电子版), 2009, 03(05): 542-548.

Meng-quan LI, Jing-ruo LI, Jiang-tao Ling. Expressions of BP1 and C-erB-2 gene in breast cancer[J/OL]. Chinese Journal of Breast Disease(Electronic Edition), 2009, 03(05): 542-548.

目的

研究BP1与C-erbB-2基因在乳腺癌组织中的表达及其相互关系。

方法

采用RT-PCR方法及免疫组织化学方法检测62例乳腺癌及配对癌旁组织中BP1、C-erbB-2基因的表达及雌激素受体(ER)、孕激素受体(PR)的表达。运用χ2 检验对各组间差别及相互关系进行分析。

结果

BP1在乳腺癌和癌旁组织中的阳性表达率分别为64.5%(40/62)和0.05%(3/62),前者明显高于后者,差异具有统计学意义(P＜0.050);BP1阳性表达率在ER阳性乳腺癌组织中为(47.3%)(18/38),在ER阴性乳腺癌组织中为91.7%(22/24),两者之间差异有统计学意义(P＜0.050);BP1阳性表达率在Ⅰ期乳腺癌中为36.3%(4/11),在Ⅱ期乳腺癌中为64.3%(27/42),在Ⅲ期乳腺癌中为100%(9/9),三者间差异有统计学意义(P＜0.050)。在乳腺癌组织中C-erbB-2阳性表达率为46.8%(29/62),C-erbB-2与BP1共阳性者23例,共阴性者16例。

结论

BP1基因在乳腺癌组织中表达高于癌旁组织,BP1表达与乳腺癌雌激素受体状态及组织学分级有关,与Cerb B-2共表达。

关键词: BP1, C-erbB-2基因, 乳腺肿瘤

Objective

To study the expressions of beta protein 1(BP1)and C-erb B-2 in breast cancer and their relationships.

Methods

RT-PCR was used to detect the expressions of BP1 and C-erb B-2,and i mmunohistochemistry was used to detect the expressions of ERand PRin breast cancer and pericaner tissues of 62 breast cancer patients.The difference and relationship bet ween groups were analyzed with Chi square test.

Results

The positive rate of BP1 expression was 64.5% (40/62 cases)in breast cancer and 0.05%(3/62 cases)in pericancer tissues,with statistically significant difference bet ween breast cancer and pericancer tissues(P＜0.050).The positive rate of BP1 expression was 47.3%(18/38 cases)in ERpositive breast cancer and 91.7% (22/24 cases)in ERnegative breast cancer,there was a statistical difference bet ween them (P＜0.050).The positive rate of BP1 expression was 36.3%(4/11 cases)in stage I breast cancer,64.3%(27/42 cases)in stage II,and 100%(9/9 cases)in stage III,with statistical difference bet ween the three groups(P＜0.050).The positive rate of C-erbB-2 expression was 46.8%(29/62 cases)in breast cancer tissue.Twenty-three cases had positive coexpression of BP1 and C-erbB-2 and 16 cases had negative coexpression of BP1 and C-erbB-2 in breast cancer tissue.

Conclusion

The BP1 expression is higher in breast cancer than in pericancer tissues,and correlated with histological grade and estrogen receptor status.Thereis coexpression of BP1 and C-erbB-2 in breast cancer.

Key words: BP1, C-erbB-2 gene, Breast neoplasms
表1 BP1、C-er b B-2和β-actin基因的引物
基因 序列 长度(bp)
BP1 sense,5'-GTATGGCCACCTCCTGTCTT-3';antisense,5'-GAGTAGATGGTCCTCGGCTT-3' 225
C-erbB-2 sense,5'-GAAGGTGAAGGTGCTTGGATC-3';antisense,5'-TAGCTCATCCCCTTGGCAATCTG-3' 342
β-actin sense,5'-ACCCCCACTGAAAAAGATGA-3';antisense,5'-ATCTTCAAACCTCCATGATG-3' 114
表2 BP1基因在乳腺癌及配对癌旁组织中的表达
组别 例数 BP1基因 χ2值 P值
阳性(例) 阳性率(%)
乳腺癌 62 40 64.5 48.738 0.000
配对癌旁 62 3 4.8
表3 62例乳腺癌中BP1的表达与ER及病理组织学分级的关系
因素 例数 BP1 χ2值 P值
阳性(例) 阳性率(%)
ER
+ 38 18 47.4 12.609 0.000
- 24 22 91.7
临床分期
Ⅰ 11 4 36.4 8.759 0.013
Ⅱ 42 27 64.3
Ⅲ 9 9 100.0
病理学分级
原位癌 9 2 22.2 6.207 0.013
浸润性癌 35 38 71.7
表4 BP1与C-erbB-2在乳腺癌组织中的表达情况
BP1 C-erbB-2 P值
阳性(例) 阴性(例)
阳性 23 17 0.035
阴性 6 16
[1]
Haga S B,Fu S,Kar p J E,et al.BP1,a new ho meobox gene,is frequentl y expressed in acute leuke mia.Leuke mia,2000,14:1867-1875.
[2]
线胤生,党诚学,阎春霞,等.同源异盒基因BP1在肺癌组织中的表达及临床意义.南方医科大学学报,2006,26:1173-1175.
[3]
Hagan S,Al Mulla F,Mallon E,et al.Reduction of Raf-1 Kinase Inhibitor Protein Expression Correlates with Breast Cancer Metastasis.Clin Cancer Res,2005,11:7392-7397.
[4]
Fu S,Sch wartz A,Stevenson H,et al.Correlation of expression of BP1,a ho meobox gene,wit h estr ogen receptor status in breast cancer.Breast Cancer Res,2003,5:82-87.
[5]
Chase M B,Fu S,Haga S B,et al.BP1,a ho meodo main-containing isf or m of DLX4,represses t he beta-gl obin gene.Mol Cell Biol,2002,22:2505-2514.
[6]
李慧,徐开林,潘秀英,等.BP1基因在成人急性白血病中的表达.中华血液学,2004,25:38-40.
[7]
Michael P D.Clinical significance of HER-2/neu overexpression:PartⅠ.Princ Pract Oncol,1999,13:1-5.
[8]
Dabiri S,Hunts man D,Makretsov N,et al.The presence of stro mal mast cells identifies a subset of invasive breast cancers with a favorable prognosis.Mod Pathol,2004,17:690-695.
[9]
Ueda Y,Wang S,Du moni N,et al.Overexpression of HER2(Er b B2)in hu man breast epit helial cells un masks TGF-induced cell motility.Biol Chem,2004,24:24 505-24 513.
[10]
aliegue S,Casellas P,Kramar A,et al.Immuno-histochemical assess ment of the peripheral benzodiazepine receptor in breast cancer and its relationship wit h survival.Clin Cancer Res,2004,10:2058-2064.
[11]
iseo M,Loprevite M,Ardizzoni A.Epider mal growth factor receptor inhibitors:a new pr ospective in t he treat ment of l ung cancer.Curr Med Che m Anti-Canc Agents,2004,4:139-148.
[12]
akino K,Day C P,Wang S C,et al.Upregulation of IKKalpha/IKKbeta by integrin-linked kinase is required f or HER2/neu-induced NF-kappa-B antiapoptotic pat h way.Oneogene,2004,23:3883-3887.
[13]
unito mo K,Inoue S,Ichihara F,et al.A case of metastatic breast cancer with out gr owth of HER2-negative cells after eradication of HER2-positive cells by hu man anti-HER2 monoclonal antibody(trastuzu mab)co mbined with docetaxel.Hu m Pathol,2004,35:379-381.
[14]
leer C G,van Golen K L,Braun T,et al.Persistent E-cadherin expression in infla mmator y breast cancer.Med Pathol,2001,14:458-464.
[15]
满,杨毅,牛瑞芳,等.同源异型盒基因BP1在乳腺癌组织中的表达及临床意义.癌症,2004,3:855-859.
[16]
cIntosh G G,Anderson J J,Milton I,et al.Deter mination of the prognostic value of cyclin D1 overexpression in breast cancer.Oncogene,1995,11:885-891.
[17]
ee A,Par k W C,Yi m H W,et al.Expression of C-er b B-2,cyclin D1 and estr ogen receptor and clinical i mplications in the invasive ductal carcino ma of the breast.Jpn J Clin Oncol,2007,37:708-714.
[18]
永春,傅四东,温小鹏,等.BP1基因和Cyclin D1基因在乳腺癌组织中的表达及意义.癌症,2007,26:709-714.
[19]
o S S,Na Y S,Yoon C S,et al.The significance of C-er b B-2 overexpression and p53 expression in patients with axillar y l y mph node negative breast cancer:a tissue micr o-array st udy.Int J Sur g Pat hol,2007,15:98-109.
[1] 李洋, 蔡金玉, 党晓智, 常婉英, 巨艳, 高毅, 宋宏萍. 基于深度学习的乳腺超声应变弹性图像生成模型的应用研究[J/OL]. 中华医学超声杂志（电子版）, 2024, 21(06): 563-570.
[2] 周荷妹, 金杰, 叶建东, 夏之一, 王进进, 丁宁. 罕见成人肋骨郎格汉斯细胞组织细胞增生症被误诊为乳腺癌术后骨转移一例[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 380-383.
[3] 河北省抗癌协会乳腺癌专业委员会护理协作组. 乳腺癌中心静脉通路护理管理专家共识[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 321-329.
[4] 刘晨鹭, 刘洁, 张帆, 严彩英, 陈倩, 陈双庆. 增强MRI 影像组学特征生境分析在预测乳腺癌HER-2 表达状态中的应用[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 339-345.
[5] 张晓宇, 殷雨来, 张银旭. 阿帕替尼联合新辅助化疗对三阴性乳腺癌的疗效及预后分析[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 346-352.
[6] 邱琳, 刘锦辉, 组木热提·吐尔洪, 马悦心, 冷晓玲. 超声影像组学对致密型乳腺背景中非肿块型乳腺癌的诊断价值[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 353-360.
[7] 程燕妮, 樊菁, 肖瑶, 舒瑞, 明昊, 党晓智, 宋宏萍. 乳腺组织定位标记夹的应用与进展[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 361-365.
[8] 涂盛楠, 胡芬, 张娟, 蔡海峰, 杨俊泉. 天然植物提取物在乳腺癌治疗中的应用[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 366-370.
[9] 朱文婷, 顾鹏, 孙星. 非酒精性脂肪性肝病对乳腺癌发生发展及治疗的影响[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 371-375.
[10] 高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[11] 韩萌萌, 冯雪园, 马宁. 乳腺癌改良根治术后桡神经损伤1例[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 117-118.
[12] 张志兆, 王睿, 郜苹苹, 王成方, 王成, 齐晓伟. DNMT3B与乳腺癌预后的关系及其生物学机制[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 624-629.
[13] 王玲艳, 高春晖, 冯雪园, 崔鑫淼, 刘欢, 赵文明, 张金库. 循环肿瘤细胞在乳腺癌新辅助及术后辅助治疗中的应用[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 630-633.
[14] 赵林娟, 吕婕, 王文胜, 马德茂, 侯涛. 超声引导下染色剂标记切缘的梭柱型和圆柱型保乳区段切除术的效果研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 634-637.
[15] 赵旭鹏, 王集琛, 田硕, 李宏召, 李修彬, 张旭. EP300 通过上调FKBP10 促进膀胱肿瘤细胞迁移和侵袭[J/OL]. 中华细胞与干细胞杂志(电子版), 2024, 14(05): 264-274.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号